Suppr超能文献

早期传代不会引起间充质干细胞免疫行为的显著改变。

Early passaging of mesenchymal stem cells does not instigate significant modifications in their immunological behavior.

机构信息

Institute of Cardiovascular Sciences, St. Boniface Hospital Research Centre, Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, Canada.

Division of Neurodegenerative Disorders, St. Boniface Hospital Research Centre, Department of Pharmacology & Therapeutics, University of Manitoba, Winnipeg, Canada.

出版信息

Stem Cell Res Ther. 2018 May 2;9(1):121. doi: 10.1186/s13287-018-0867-4.

Abstract

BACKGROUND

Bone marrow-derived allogeneic mesenchymal stem cells (MSCs) from young healthy donors are immunoprivileged and their clinical application for regenerative medicine is under evaluation. However, data from preclinical and initial clinical trials indicate that allogeneic MSCs after transplantation provoke a host immune response and are rejected. In the current study, we evaluated the effect of an increase in passage number in cell culture on immunoprivilege of the MSCs. Since only limited numbers of MSCs can be sourced at a time from a donor, it is imperative to expand them in culture to meet the necessary numbers required for cell therapy. Presently, the most commonly used passages for transplantation include passages (P)3-7. Therefore, in this study we included clinically relevant passages, i.e., P3, P5, and P7, for evaluation.

METHODS

The immunoprivilege of MSCs was assessed with the mixed leukocyte reaction assay, where rat MSCs were cocultured with peripheral blood leukocytes for 72 h. Leukocyte-mediated cytotoxicity, apoptosis (Bax/Bcl-xl ratio), leukocyte proliferation, and alterations in cellular bioenergetics in MSCs were assessed after the coculture. Furthermore, the expression of various oxidized phospholipids (oxidized phosphatidylcholine (ox-PC)) was analyzed in MSCs using a lipidomic platform. To determine if the ox-PCs were acting in tandem with downstream intracellular protein alterations, we performed proteome analysis using a liquid chromatography/mass spectrometry (LC/MS) proteomic platform.

RESULTS

Our data demonstrate that MSCs were immunoprivileged at all three passages since coculture with leukocytes did not affect the survival of MSCs at P3, P5, and P7. We also found that, with an increase in the passage number of MSCs, leukocytes did not cause any significant effect on cellular bioenergetics (basal respiration rate, spare respiratory capacity, maximal respiration, and coupling efficiency). Interestingly, in our omics data, we detected alterations in some of the ox-PCs and proteins in MSCs at different passages; however, these changes were not significant enough to affect their immunoprivilege.

CONCLUSIONS

The outcome of this study demonstrates that an increase in passage number (from P3 to P7) in the cell culture does not have any significant effect on the immunoprivilege of MSCs.

摘要

背景

来自年轻健康供体的骨髓源性同种异体间充质干细胞(MSCs)具有免疫特权,其用于再生医学的临床应用正在评估中。然而,临床前和初步临床试验的数据表明,同种异体 MSC 移植后会引发宿主免疫反应并被排斥。在本研究中,我们评估了细胞培养中传代数增加对 MSC 免疫特权的影响。由于每次只能从供体获得有限数量的 MSC,因此必须在培养中进行扩增,以满足细胞治疗所需的数量。目前,移植中最常用的传代数包括 P3-7。因此,在这项研究中,我们包括了临床相关的传代数,即 P3、P5 和 P7 进行评估。

方法

通过混合白细胞反应测定法评估 MSC 的免疫特权,其中大鼠 MSC 与外周血白细胞共培养 72 小时。共培养后评估白细胞介导的细胞毒性、凋亡(Bax/Bcl-xl 比值)、白细胞增殖以及 MSC 细胞能量代谢的变化。此外,使用脂质组学平台分析 MSC 中各种氧化磷脂(氧化磷脂酰胆碱(ox-PC))的表达。为了确定 ox-PC 是否与下游细胞内蛋白改变协同作用,我们使用液相色谱/质谱(LC/MS)蛋白质组学平台进行蛋白质组分析。

结果

我们的数据表明,在所有三个传代中 MSC 都具有免疫特权,因为白细胞共培养不会影响 P3、P5 和 P7 时 MSC 的存活。我们还发现,随着 MSC 传代数的增加,白细胞不会对细胞能量代谢(基础呼吸率、备用呼吸能力、最大呼吸和偶联效率)产生任何显著影响。有趣的是,在我们的组学数据中,我们在不同传代的 MSC 中检测到一些 ox-PC 和蛋白的改变;然而,这些变化还不足以影响它们的免疫特权。

结论

这项研究的结果表明,细胞培养中传代数的增加(从 P3 增加到 P7)对 MSC 的免疫特权没有任何显著影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验